# nanosynth group confident of further positive developments in H2

- Link: https://www.directorstalkinterviews.com/nanosynth-group-confident-of-further-positive-developments-in-h2/4121070740
- Published: 2022-06-30T07:29:11+01:00
- Author: Giles

**nanosynth Group plc** (LON:NNN), the AIM quoted company specialising in the synthesis
and application of nanoparticles to create new and improve existing products, has
announced its final audited results for the year ended 31 December 2021.

The Company also announced that the Company’s Annual General Meeting will be held
at 9am on 22 July 2022 at the London Marriott Hotel Maida Vale, Plaza Parade, Maida
Vale, NW6 5RP.

The Company’s annual report and accounts, Notice of AGM and Forms of Proxy will 
be dispatched to shareholders later today and will shortly be available on the website
at www.nanosynthgroup.com

**CHAIRMAN’S STATEMENT**

**Overview**

The last eighteen months has been a period of major change at nanosynth group plc(
nnn) with a new name, a new board and a new direction. During the year the Group
refocused on the development and commercialisation of its core nano-particle platform
technology and dispensed with non-core activities, including the return of Cloudveil
Limited to its founders and, the disposal of the majority of Gyrometric Systems 
Ltd. The Group also announced a strategic review and has emerged in a stronger position
than this time last year with a healthy balance sheet, a clear and achievable business
strategy and a new team positioned to deliver against the Group’s strategic goals.

**Board changes**

The Company implemented a number of board changes in the period.  The major challenge
for the new board was a complete strategic review.  The Board was also keen to build
on the innovations behind the anti-viral face mask and develop further products 
using the same technology, alongside the development of products for the agricultural
sector, which had been the founding principle behind Pharm2Farm (P2F).

**Financials**

With a year of substantial change and complete refocus, the results for the 2021
financial year provide limited meaningful insight into the future of the business
and in fact incorporate costs associated with the required strategic shift.

Operating expenses related to continuing operations before current asset impairments
increased to £2,538k from £960k in 2020 reflecting the greater activity within the
Group and incorporating a number of one-off costs required to reposition the business.
Revenue from continuing operations increased to £209k in 2021 from £1k in 2020, 
which was derived solely from the P2F division. 

During the period the Company raised £939,225 net of costs through the issue of 
new shares as a result of the exercise of warrants and options. In addition, £1,505,000
was received during this financial year in respect of shares issued in the previous
period.

Cash as at 31^(st) December 2021 was £3.8m, and at the date of this report, the 
Group had net cash of £1.8m which is considered to be more than sufficient to cover
the expected working capital requirements of the Group for at least the next twelve
months.

**Strategic review**

As a result of the deep strategic review, the decision was made to evolve the Group’s
mask strategy to focus on licensing the core anti-viral technology into the market
rather than manufacturing masks directly.  As a result of market changes it was 
not considered financially viable to continue manufacturing masks and, as previously
notified, _the mask machine was disposed of and_ the existing stock has been fully
provided for in these accounts given the likely incremental cost of readying that
stock for commercial sale.  The remaining masks that have been manufactured will
be made available to good causes including local hospitals and care homes.

The ground-breaking technology that was developed for the anti-viral face masks 
is being further refined for use in the HVAC market through a joint venture company,
Virosynth, that has been formed with a leading vertically integrated media manufacturer,
Volz Luftfilter GmbH. Through the JV arrangement, nanosynth expects to benefit from
the heightened awareness of, and demand for, cleaner air in all public environments.

Beyond HVAC, there are seven additional specific market verticals that have been
identified for the development and application of nanoparticle technology with strategic
partners. These areas include animal health and wellbeing, cosmetics, medical, plants,
food and drink, functional coatings and electronics.  In each of these areas, specific
use-cases and development projects have been defined and strategic partners have
been identified. The Company is currently in discussion with a number of major companies
and trading partners within the seven identified markets and will be progressing
these discussions in order to target the conclusion of successful commercial agreements
within the second half of 2022, galvanising the confidence and clear value the Board
see in nanosynth group and its new commercial strategy. 

At this point, it is noted the future strategy shared on 1 June 2022 is not impacted
by the current situation surrounding Ukraine nor the associated sanctions imposed
on Russia other than the global shift in commodity prices, a risk we aim to manage
with our target trading partners and supply agreements.

**Richard Clarke**

Non-Executive Chairman

29 June 2022

> **Mark Duffin, Chief Executive of nanosynth Group, commented**:
> “I would like to thank all of the Company’s shareholders for their support. The
> Board is firmly focused on delivering concrete agreements with commercial parties
> and looks forward to updating shareholders as it progresses its various initiatives.
> At the beginning of the year, the Board was considering various M&A opportunities
> however, in the current economic climate this is not now a near term focus though
> the Company will always consider opportunities where it can deliver value to shareholders
> and build scale to its operations.  After the groundwork that has been carried
> out during the year to date, I am confident that the second half of 2022 will 
> see further positive developments at nanosynth and we look forward with renewed
> optimism.”

Share on:
